» Articles » PMID: 9750244

Assessing the Sensitivity of Regression Results to Unmeasured Confounders in Observational Studies

Overview
Journal Biometrics
Specialty Public Health
Date 1998 Sep 29
PMID 9750244
Citations 260
Authors
Affiliations
Soon will be listed here.
Abstract

This paper presents a general approach for assessing the sensitivity of the point and interval estimates of the primary exposure effect in an observational study to the residual confounding effects of unmeasured variable after adjusting for measured covariates. The proposed method assumes that the true exposure effect can be represented in a regression model that includes the exposure indicator as well as the measured and unmeasured confounders. One can use the corresponding reduced model that omits the unmeasured confounder to make statistical inferences about the true exposure effect by specifying the distributions of the unmeasured confounder in the exposed and unexposed groups along with the effects of the unmeasured confounder on the outcome variable. Under certain conditions, there exists a simple algebraic relationship between the true exposure effect in the full model and the apparent exposure effect in the reduced model. One can then estimate the true exposure effect by making a simple adjustment to the point and interval estimates of the apparent exposure effect obtained from standard software or published reports. The proposed method handles both binary response and censored survival time data, accommodates any study design, and allows the unmeasured confounder to be discrete or normally distributed. We describe applications on two major medical studies.

Citing Articles

The Impact of Idiopathic Intracranial Hypertension on Cardiovascular Disease Risk Among UK Women: An Obesity-Adjusted Analysis.

Azzam A, Morsy M, Ellabban M, Morsy A, Zahran A, Nassar M ASIDE Intern Med. 2025; 1(1):1-11.

PMID: 39830613 PMC: 11739732. DOI: 10.71079/h1fr8h68.


unmconf : an R package for Bayesian regression with unmeasured confounders.

Hebdon R, Stamey J, Kahle D, Zhang X BMC Med Res Methodol. 2024; 24(1):195.

PMID: 39244581 PMC: 11380322. DOI: 10.1186/s12874-024-02322-2.


Efficacy of traditional Chinese medicine on shortening the negative conversion time of SARS-CoV-2 ribonucleic acid in patients with mild COVID-19: a retrospective cohort study.

Chen Y, Yang M, Tian Y, Chen X, Lu W, Wei H Sci One Health. 2024; 2:100049.

PMID: 39077047 PMC: 11262282. DOI: 10.1016/j.soh.2023.100049.


A future of data-rich pharmacoepidemiology studies: transitioning to large-scale linked electronic health record + claims data.

Schneeweiss S, Desai R, Ball R Am J Epidemiol. 2024; 194(2):315-321.

PMID: 39013780 PMC: 11815500. DOI: 10.1093/aje/kwae226.


US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.

Duke E, Bradford D, Sinha A, Mishra-Kalyani P, Lerro C, Rivera D J Clin Oncol. 2024; 42(25):3047-3057.

PMID: 38917371 PMC: 11365752. DOI: 10.1200/JCO.24.00546.